Phase II data support potential for Roche ’s novel anti-VEGF/anti-angiopoietin-2 bispecific antibody, RG7716, for people with diabetic macular edema

Roche today announced encouraging results from the Phase II BOULEVARD study.
Source: Roche Investor Update - Category: Pharmaceuticals Source Type: news